A major obstacle in the treatment of infections and other diseases of the brain is the blood-brain barrier, which prevents systemically delivered therapeutic drugs from reaching the brain.
A new study suggests patients hospitalized with pneumonia may be at serious risk of new or worsening heart problems. The study is published in the July 15 issue of Clinical Infectious Diseases, currently available online.
Breastfeeding for a period of thirteen months or more has been shown to reduce the mother?s the risk of developing rheumatoid arthritis (RA), according to new data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
The targeted use of an anti-estrogen drug could prolong the life of some ovarian cancer patients by up to three years, and delay the use of chemotherapy in others, revealed by researchers at the University of Edinburgh.
Higher immune cell counts in AIDS patients treated with highly active antiretroviral therapy (HAART) are associated a lower incidence of Kaposi sarcoma and non-Hodgkin lymphoma.
A gene responsible for the single most common cause of hearing loss among white adults, otosclerosis, has been identified for the first time, a scientist told the annual conference of the European Society of Human Genetics in Nice, France. Melissa Thys, from the Department of Medical Genetics, University of Antwerp, Belgium, said that this finding may be a step towards new treatments for otosclerosis, which affects approximately one in 250 people.
Rare, previously undetectable drug-resistant forms of HIV have been identified by Yale School of Medicine researcher Michael Kozal, M.D., using an innovative genome sequencing technology that quickly detects rare viral mutations.
The University of Delaware has been awarded $11 million from the National Institutes of Health for leading-edge, “translational” research on osteoarthritis that includes a unique mentoring program to foster the development of women biomedical researchers at UD.
Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a European study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE? (infliximab) over two years experienced significant improvement in spinal mobility.